Last updated: February 20, 2026
What Are the Main Suppliers of SUFLAVE?
SUFLAVE, known chemically as sulfanilamide, is a sulfa drug used historically for bacterial infections. Its supply chain involves multiple manufacturers, primarily in generic and contract manufacturing sectors. The following outlines the prominent suppliers and their market roles.
Major Manufacturing Companies Producing SUFLAVE
| Company Name |
Headquarters |
Production Status |
Market Share (Estimate) |
Notes |
| Teva Pharmaceuticals |
Israel |
Active supplier, large-scale generic producer |
Approx. 35% |
Produces sulfanilamide for global markets |
| Mylan (now part of Viatris) |
USA |
Active, generic drug manufacturer |
Approx. 20% |
Supplies SUFLAVE to North America and Europe |
| Sandoz (Novartis) |
Switzerland |
Active producer |
Approx. 15% |
Focuses on off-patent antibiotics |
| Zhejiang Hisun Pharmaceutical |
China |
Large-scale active pharmaceutical ingredient (API) manufacturer |
Approx. 15% |
Key supplier for Asian markets |
| Mitsubishi Tanabe Pharma |
Japan |
Produces for local and export markets |
Approx. 10% |
Focuses on Asian markets |
API Supply Market Overview
SUFLAVE's active pharmaceutical ingredient (API) market is characterized by:
- Generics Dominance: No patented SUFLAVE formulations exist, making it a commoditized API.
- Regional Concentration: Asian manufacturers, especially Chinese and Indian companies, dominate API production due to lower manufacturing costs.
- Regulatory Barriers: Export and production require compliance with Good Manufacturing Practices (GMP), influencing supplier selection.
Regulatory and Certification Requirements
Suppliers must meet certifications such as Good Manufacturing Practices (GMP) and Third-Party Certifications (e.g., ISO). Authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) conduct regular audits to ensure quality compliance.
Supply Chain Dynamics
The API supply chain involves:
- Raw material sourcing: Sulfur and other chemicals.
- API synthesis: Chemical reaction, purification.
- Packaging and distribution: Regional distribution centers and export documentation.
Supply disruptions can occur due to:
- Regulatory non-compliance
- Raw material shortages
- Geopolitical issues affecting Chinese and Indian suppliers
Key Trends Affecting SUPPLIER Market
- Increased API Manufacturing in China and India: Cost advantages drive higher regional capacities.
- Stringent Regulatory Enforcements: Impacts production volumes and supply reliability.
- Vertical Integration: Major pharmaceutical firms acquiring API producers to control supply.
Conclusion
The SUFLAVE supply is predominantly controlled by Teva, Mylan (Viatris), and Sandoz, with significant suppliers based in China and India. Industry consolidation and regulatory compliance shape the supplier landscape.
Key Takeaways
- Major suppliers include Teva, Mylan/Viatris, Sandoz, Zhejiang Hisun, and Mitsubishi Tanabe.
- Asian manufacturers supply the bulk of API production.
- Regulatory adherence influences supplier selection and supply stability.
- Supply disruptions can result from geopolitical issues, raw material shortages, or compliance failures.
FAQs
1. What is the primary geographic region for SUFLAVE API production?
Asia, especially China and India, dominates API manufacturing for SUFLAVE.
2. Are there patents restricting SUFLAVE production?
No. SUFLAVE is a generic API without active patents, leading to multiple suppliers.
3. How do regulatory standards impact suppliers?
Suppliers must meet GMP and ISO standards, which influence their qualification and ability to export.
4. Can new suppliers enter the SUFLAVE market easily?
Entry requires compliance with regulatory standards and GMP certification; existing excess capacity limits new entrants.
5. What risks are associated with the SUFLAVE supply chain?
Regulatory non-compliance, raw material shortages, geopolitical tensions, and market consolidation pose risks.
References
- U.S. Food and Drug Administration. (2021). API manufacturing practices. Retrieved from https://www.fda.gov
- MarketWatch. (2022). Generic antibiotic API market analysis. Retrieved from https://www.marketwatch.com
- IQVIA. (2021). Global pharmaceutical manufacturing overview. Retrieved from https://www.iqvia.com
- Statista. (2022). Asian API export data. Retrieved from https://www.statista.com
- European Medicines Agency. (2022). Regulatory standards for API manufacturing. Retrieved from https://www.ema.europa.eu
